Results 61 to 70 of about 3,797 (192)

Cost-effectiveness of narlaprevir in the chronic hepatitis C (genotype 1) therapy in treatment-naïve patients and relapsers

Журнал инфектологии, 2016
In the treatment of chronic hepatitis C (CHC) protease inhibitors (PI) are actively used. The aim of this analysis was to evaluate the cost-effectiveness of narlaprevir and simeprevir in the CHC (genotype 1) therapy in treatment-naïve patients and ...
D. A. Gusev, A. V. Rudakova, A. N. Uskov, L. N. Konovalova, Yu. V. Lobzin   +4 more
doaj  

Remission of long-term hepatic and renal disease induced by HCV after direct-acting antivirals therapy

Brazilian Journal of Nephrology, 2020
In addition to liver disease, the hepatitis C virus (HCV) has been associated with autoimmune phenomena, such as mixed cryoglobulin and glomerulonephritis (GN). Until recently, both chronic hepatitis and HCV extra-hepatic manifestations were treated with
Raissa M Arruda, Andrea D Batista, Norma A Filgueira, Izolda F Moura, Luis H Sette, Edmundo P Lopes   +5 more
doaj   +2 more sources

How Clinical Pharmacology Can Support Clinical Trial Diversity and Inclusion

Clinical and Translational Science, Volume 18, Issue 9, September 2025.
ABSTRACT Enrolling diverse populations during early clinical trial development and planning for diversity plans could be challenging. In 2024, the Diversity and Inclusion Clinical Pharmacology Leadership Group Working Group (D&I CPLG WG) from The International Consortium for Innovation and Quality in Pharmaceutical Development (IQ) collaborated with ...
Michael Z. Liao, Aarti Sawant, Brian Corrigan, Sebastian Haertter, Yasuto Otsubo, Islam R. Younis, Sreeneeranj Kasichayanula, Rashmi Mehta   +7 more
wiley   +1 more source

Efficacy, safety and pharmacokinetics of simeprevir and TMC647055/ritonavir with or without ribavirin and JNJ-56914845 in HCV genotype 1 infection [PDF]

, 2017
Background: A Phase 2a, open-label study (NCT01724086) was conducted to assess the efficacy and safety of a once-daily, 2-direct-acting-antiviral-agent (2-DAA) combination of simeprevir + TMC647055/ritonavir ± ribavirin and of the 3-DAA combination of ...
Hans Orlent, Vijgen, Leen, Sven Francque, Luo, Donghan, Eva Hoeben, Schattenberg, Jörn Markus, Nevens, Frederik, Horsmans, Yves, Hoeben, Eva, Frederik Nevens, Kakuda, Thomas N., Kakuda, Thomas N, Christophe Moreno, Schattenberg, Jörn M, Francque, Sven, Hans Van Vlierberghe, Pieter Van Remoortere, Kakuda, Thomas T.N., Vandebosch, An, Keikawus Arastéh, Horsmans, Y., Jacquemyn, Bert, Orlent, Hans, Verloes, René, Arasteh, Keikawus, Thomas N. Kakuda, René Verloes, Bourgeois, Stefan, Stefan Bourgeois, Moreno, Christophe, Donghan Luo, Bert Jacquemyn, Schattenberg, Jorn M., Peter Buggisch, Leen Vijgen, Van Vlierberghe, Hans, Buggisch, Peter, An Vandebosch, Yves Horsmans, Jörn M. Schattenberg, Van Remoortere, Pieter   +40 more
core   +1 more source

Acute liver disorders in the third trimester—AFLP, HELLP and infectious hepatitis—update on pathology, diagnosis and management

The Obstetrician &Gynaecologist, Volume 27, Issue 3, Page 180-196, July 2025.
Key content The epidemiology and pathophysiology of AFLP, HELLP syndrome and infectious viral hepatitis in late pregnancy. Clinical presentation, diagnosis and management of these conditions. Complications (maternal and fetal) and how these can be managed. The role of a multidisciplinary team in management.
Victor N. Chilaka, Mohammed Bashir, Theodore Ngatchu, Badreldeen Ahmed, Justin C. Konje   +4 more
wiley   +1 more source

Long‐Term Follow‐Up of Neuropsychiatric Symptoms After Sustained Virological Response to Interferon‐Free and Interferon‐Based Hepatitis C Virus Treatment

Journal of Viral Hepatitis, Volume 32, Issue 4, April 2025.
ABSTRACT Chronic hepatitis C virus (HCV) infection can be associated with neuropsychiatric symptoms like fatigue and cognitive impairment, independent of the liver status. The present study aims to assess changes in the pattern and extent of neuropsychological symptoms after successful treatment with interferon (IFN)‐based and IFN‐free therapy.
Meike Dirks, Ann‐Katrin Hennemann, Gerrit M. Grosse, Anika Beer, Henning Pflugrad, Kim Haag, Ramona Schuppner, Katja Deterding, Markus Cornberg, Heiner Wedemeyer, Karin Weissenborn   +10 more
wiley   +1 more source

Simeprevir plus sofosbuvir (12 and 8 weeks) in hepatitis C virus genotype 1-infected patients without cirrhosis: OPTIMIST-1, a phase 3, randomized study

, 2016
Effective antiviral therapy is essential for achieving sustained virological response (SVR) in hepatitis C virus (HCV)-infected patients. The phase 2 COSMOS study reported high SVR rates in treatment-naive and prior null-responder HCV genotype (GT) 1 ...
Etzkorn, Kyle, Schiff, Eugene, Witek, James, Rojter, Sergio, Fevery, Bart, Kwo, Paul, Kalmeijer, Ronald, Bernstein, David, Davis, Mitchell, Ruane, Peter, Sinha, Rekha, De La Rosa, Guy, Nahass, Ronald, Younes, Ziad, Peeters, Monika, Gitlin, Norman, Scott, Jane, Lenz, Oliver   +17 more
core   +1 more source

Sofosbuvir in Combination with Simeprevir +/- Ribavirin in Genotype 4 Hepatitis C Patients with Advanced Fibrosis or Cirrhosis: A Real-World Experience from Belgium.

PLoS ONE, 2017
IntroductionHepatitis C virus (HCV) is a major global health issue and successful treatment has been associated with a reduction of risk of all-cause mortality.
Delphine Degré, Thomas Sersté, Luc Lasser, Jean Delwaide, Peter Starkel, Wim Laleman, Philippe Langlet, Hendrik Reynaert, Stefan Bourgeois, Thomas Vanwolleghem, Sergio Negrin Dastis, Thierry Gustot, Anja Geerts, Christophe Van Steenkiste, Chantal de Galocsy, Antonia Lepida, Hans Orlent, Christophe Moreno   +17 more
doaj   +1 more source

The Malignant Transformation of Viral Hepatitis to Hepatocellular Carcinoma: Mechanisms and Interventions

MedComm, Volume 6, Issue 3, March 2025.
The malignant transformation from chronic viral hepatitis to hepatocellular carcinoma (HCC) involves intricate interactions among viral, host, and environmental factors. Key drivers of this transformation include viral integration, genomic instability, epigenetic modifications, oxidative stress, gut microbiota dysbiosis, chronic inflammation, immune ...
Huimin Yuan, Ruochen Xu, Senlin Li, Mengzhu Zheng, Qingyi Tong, Ming Xiang, Yonghui Zhang   +6 more
wiley   +1 more source

A NEW HEALTH TECHNOLOGY ASSESSMENT SYSTEM FOR JAPAN? SIMULATING THE POTENTIAL IMPACT ON THE PRICE OF SIMEPREVIR

, 2017
Objectives:Japanese authorities have announced a plan to introduce a health technology assessment (HTA) system in 2016. This study assessed the potential impact of such a policy on the price of the antivirologic drug simeprevir.Methods:Taking the ...
Jörg Mahlich, Bruno Rossi, Isao Kamae
core   +1 more source